What one share of Macrogenics holds
We are a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms.
Macrogenics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.76 |
|---|---|
| Profit | −$0.23 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$1.03 |
| Cash and investments | $1.79 |
| Book value | $0.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $8.48 | −$0.04 | $0.43 | −$2.50 | — | — |
| 2014 | $1.75 | −$1.40 | $0.13 | −$1.33 | — | $4.33 |
| 2015 | $3.17 | −$0.63 | $0.29 | −$0.72 | — | $9.12 |
| 2016 | $2.65 | −$1.69 | $0.33 | −$1.59 | — | $7.71 |
| 2017 | $4.37 | −$0.54 | $0.81 | −$0.42 | — | $8.12 |
| 2018 | $1.47 | −$4.19 | $0.61 | −$4.35 | — | $5.73 |
| 2019 | $1.33 | −$3.16 | $0.09 | −$2.88 | — | $4.71 |
| 2020 | $2.00 | −$2.47 | $0.11 | −$2.25 | — | $5.26 |
| 2021 | $1.29 | −$3.37 | $0.10 | −$2.50 | — | $3.91 |
| 2022 | $2.47 | −$1.95 | $0.06 | −$1.47 | — | $2.30 |
| 2023 | $0.95 | −$0.15 | $0.03 | −$1.29 | — | $2.46 |
| 2024 | $2.39 | −$1.07 | $0.06 | −$1.15 | — | $1.85 |
| 2025 | $2.37 | −$1.18 | $0.03 | −$1.31 | — | $0.88 |
Common questions about Macrogenics
How much does one share of Macrogenics earn?
Over the last 12 months, Macrogenics lost $0.23 for each share on $2.76 of sales.
Does Macrogenics pay a dividend?
Macrogenics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Macrogenics’s book value per share?
Macrogenics’s book value is $0.67 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Macrogenics have?
Each share of Macrogenics has $1.79 of cash and investments, as of June 30, 2026.
What is Macrogenics’s free cash flow per share?
−$1.03 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Macrogenics bought back shares?
Macrogenics’s share count rose about 822% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.